# Pfizer Inc. – Consensus ‘buy’ rating and 15.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/pfizer-inc.consensus-buy-rating-and-15.2-upside-potential/4121152546
- Published: 2024-04-19T13:53:19+01:00
- Author: Charlotte Edwards

**Pfizer Inc.** which can be found using ticker (PFE) now have 22 market analysts
covering the stock. The analyst consensus now points to a rating of ‘buy’. The target
price High/Low ranges between $42.37 and $24.48 calculating the average target price
we see $29.28. Given that the stocks previous close was at $25.42 and the analysts
are correct then there would likely be a percentage uptick in value of 15.2%. There
is a 50 day moving average of $27.14 and the 200 day moving average is $30.79. The
market capitalization for the company is 143.77B. The current share price for the
company is: $25.39 USD

 The potential market cap would be $165,603,484,247 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 68.62, revenue per share of $10.37
and a 1.55% return on assets.

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged
in the discovery, development, manufacture, marketing, sale and distribution of 
biopharmaceutical products around the world. The Company operates through two segments:
Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business.
PC1 is its global contract development and manufacturing organization and supplier
of specialty active pharmaceutical ingredients. The Company’s primary care products
include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, 
Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty
care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra,
Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin,
and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products
include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.

Share on:
